Stock listing

Dusseldorf:A8D AB Science SA Aktie

German listing (Dusseldorf) of AB Science SA · home listing Euronext:AB

Follow AB Science SA into a list and get an email when it puts out news.

Home listing price · EURONEXT:AB

€0.543 EUR -0.008 (-1.5%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:AB

AB Science SA logo
Ticker
Dusseldorf:A8D
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

Revenues for the first half of 2026 and update on AB Science’s activities

Oct 9, 2026

AB Science today reports its revenues for the first half of 2026 and provides an update on its activities

Oct 9, 2026

AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection

Sep 29, 2026

AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques

Sep 29, 2026

AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

Aug 16, 2026

AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

Aug 10, 2026

AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros

Aug 9, 2026

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

Jul 10, 2026

AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques

Jul 9, 2026

AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML

Jun 29, 2026

All AB Science SA news

Financings

  • Private placement of new ordinary shares with share warrants attached (ABSA)

    Aug 10, 2026 · US$16.4M

    Closed: €14.2M raised · €0.61 a share · 1 warrant at €1 for 60 months

    Buyers: Existing long-term investor (EUR 12 million); Stéphane Ledermann

    Insiders: The CEO, Stéphane Ledermann, also contributed to the financing

    Use of proceeds: Fund R&D programs, mainly AB8939 in acute myeloid leukemia, masitinib in ALS, and nearer-term value-creation projects

    Closed Aug 10, 2026

Read by 6ix AI from the company's releases

Decks

AB Science SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
28 in the last 12 months · 50 in all · newest Oct 9, 2026 · oldest 2025
Decks
7 decks · latest January 2026

Where AB Science SA is listed

ListingExchangeCountryCurrency
Euronext:AB · Home listingEuronextFranceEUR
LSE:0Q77LSEUnited KingdomEUR
LS Exchange:A1CXBGLS ExchangeGermanyEUR
OTC:ABSCFOTCUnited StatesUSD
Lang & Schwarz:A1CXBGLang & SchwarzGermanyEUR
gettex:A8DgettexGermanyEUR
Aquis:ABPAquisUnited KingdomEUR
Turquoise:ABPTurquoiseUnited KingdomEUR
Aquis:ABPAquisUnited KingdomEUR
Dusseldorf:A8D · This pageDusseldorfGermanyEUR
Frankfurt:A8DFrankfurtGermanyEUR
Hamburg:A8DHamburgGermanyEUR
Munich:A8DMunichGermanyEUR
Stuttgart:A8DStuttgartGermanyEUR
Tradegate:A8DTradegateGermanyEUR

Log in to ask 6ix AI your own questions about AB Science SA.